Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Monti

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumorsSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Diagnostic effectiveness of [<sup>18</sup>F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective studyGianluca Bottoni, Francesco Fiz, Matteo Puntoni, et al.
British Journal of Cancer|August 1, 2021
Circulating androgen receptor gene amplification and resistance to <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trialUgo De Giorgi, Maddalena Sansovini, Stefano Severi, et al.
Frontiers in Oncology|April 16, 2021
Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade GliomaDonatella Arpa, Elisabetta Parisi, Giulia Ghigi, et al.
Annals of Surgical Oncology|May 28, 2013
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)Giovenzio Genestreti, Luca Ampollini, Marco Angelo Burgio, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2023
Radioligand therapies in cancer: mapping the educational landscape in EuropeValentina Bugani, Luca Battistelli, Maddalena Sansovini, et al.
Stem Cell Research & Therapy|July 25, 2015
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contactRachele Ciccocioppo, Giuseppina C Cangemi, Peter Kruzliak, et al.
JCO Oncology Practice|September 16, 2020
How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment ToolFrancesca Fabbri, Giorgia Gentili, Patrizia Serra, et al.
European Journal of Radiology|June 17, 2021
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CTGianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumorsSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2023
Diagnostic effectiveness of [<sup>18</sup>F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective studyGianluca Bottoni, Francesco Fiz, Matteo Puntoni, et al.
British Journal of Cancer|August 1, 2021
Circulating androgen receptor gene amplification and resistance to <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trialUgo De Giorgi, Maddalena Sansovini, Stefano Severi, et al.
Frontiers in Oncology|April 16, 2021
Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade GliomaDonatella Arpa, Elisabetta Parisi, Giulia Ghigi, et al.
Annals of Surgical Oncology|May 28, 2013
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)Giovenzio Genestreti, Luca Ampollini, Marco Angelo Burgio, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 14, 2023
Radioligand therapies in cancer: mapping the educational landscape in EuropeValentina Bugani, Luca Battistelli, Maddalena Sansovini, et al.
Stem Cell Research & Therapy|July 25, 2015
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contactRachele Ciccocioppo, Giuseppina C Cangemi, Peter Kruzliak, et al.
JCO Oncology Practice|September 16, 2020
How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment ToolFrancesca Fabbri, Giorgia Gentili, Patrizia Serra, et al.
European Journal of Radiology|June 17, 2021
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CTGianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, et al.
Pageof 9